Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Mediolanum International Funds Ltd

Mediolanum International Funds Ltd increased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 5.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,449 shares of the biopharmaceutical company’s stock after purchasing an additional 224 shares during the period. Mediolanum International Funds Ltd’s holdings in Regeneron Pharmaceuticals were worth $3,118,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of REGN. State Street Corp raised its holdings in shares of Regeneron Pharmaceuticals by 1.3% in the third quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company’s stock worth $5,153,603,000 after acquiring an additional 61,277 shares during the last quarter. International Assets Investment Management LLC raised its stake in Regeneron Pharmaceuticals by 86,013.3% in the 3rd quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock valued at $926,078,000 after purchasing an additional 879,916 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in Regeneron Pharmaceuticals by 1.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 673,261 shares of the biopharmaceutical company’s stock valued at $707,759,000 after purchasing an additional 11,499 shares during the last quarter. Swiss National Bank lifted its holdings in Regeneron Pharmaceuticals by 0.6% in the 3rd quarter. Swiss National Bank now owns 321,600 shares of the biopharmaceutical company’s stock valued at $338,079,000 after purchasing an additional 2,000 shares in the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 1.3% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 301,508 shares of the biopharmaceutical company’s stock worth $316,957,000 after purchasing an additional 3,866 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

REGN has been the subject of a number of analyst reports. Piper Sandler cut their price objective on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating for the company in a research report on Monday, January 27th. UBS Group downgraded Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price target for the company from $1,130.00 to $738.00 in a report on Thursday, January 16th. Morgan Stanley decreased their price objective on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. Barclays dropped their target price on Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. Finally, Evercore ISI decreased their price target on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating on the stock in a research note on Thursday, October 24th. One research analyst has rated the stock with a sell rating, seven have given a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $1,004.57.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock opened at $672.98 on Friday. Regeneron Pharmaceuticals, Inc. has a 52 week low of $666.25 and a 52 week high of $1,211.20. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. The stock has a market cap of $73.95 billion, a P/E ratio of 16.65, a price-to-earnings-growth ratio of 1.62 and a beta of 0.10. The stock has a 50 day moving average of $720.81 and a 200-day moving average of $924.07.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.